Amyloidosis: New strategies for treatment

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 12, 2003, Pages 1608-1613

  Hirschfield, G M ^a   Hawkins, P N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloidosis; Glycosaminoglycans; Serum amyloid P component; Therapeutics

Indexed keywords

1 [6 (2 CARBOXYPYRROLIDIN 1 YL) 6 OXOHEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID; 1,3 PROPANEDISULFONIC ACID; AMYLOID; AMYLOID A PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; BETA SECRETASE; CAPTOPRIL; DERMATAN SULFATE; DICLOFENAC; DIMER; DISULFIDE; GAMMA SECRETASE; HEPARAN; IMMUNOSUPPRESSIVE AGENT; N ACETYLGLUCOSAMINE; PENTRAXIN; PREALBUMIN; PROTEIN ANTIBODY; PROTEOGLYCAN; SERUM AMYLOID A; SERUM AMYLOID P; SULFONIC ACID DERIVATIVE; SULFUR DERIVATIVE; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ALLELE; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID NEUROPATHY; AMYLOIDOSIS; AUTOIMMUNITY; B LYMPHOCYTE; BETA SHEET; CAUSE OF DEATH; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIASTEREOISOMER; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; EPIMER; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; LIVER TRANSPLANTATION; MASS SPECTROMETRY; MATURITY ONSET DIABETES MELLITUS; MENINGOENCEPHALITIS; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; TISSUE STRUCTURE; VASCULAR AMYLOIDOSIS;

EID: 0142124707     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(03)00169-9     Document Type: Short Survey

References (19)

1. Botto M., Hawkins P.N., Bickerstaff M.C.M., Herbert J., Bygrave A.E., McBride A., Hutchinson W.L., Tennent G.A., Walport M.J., Pepys M.B. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nature Medicine. 3:1997;855-859.
2. Bucciantini M., Giannoni E., Chiti F., Baroni F., Formigli L., Zurdo J., Taddei N., Ramponi G., Dobson C.M., Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 416:2002;507-511.
3. Dobson, C. M. (2001). Protein folding and its links with human disease. Biochemical Society Symposium, 1-26.
4. Dominguez D.I., De Strooper B. Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. Trends in Pharmacological Sciences. 23:2002;324-330.
5. Gillmore J.D., Lovat L.B., Persey M.R., Pepys M.B., Hawkins P.N. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 358:2001;24-29.
6. Hawkins P.N. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Current Opinion in Nephrology and Hypertension. 11:2002;649-655.
7. Hrncic R., Wall J., Wolfenbarger D.A., Murphy C.L., Schell M., Weiss D.T., Solomon A. Antibody-mediated resolution of light chain-associated amyloid deposits. American Journal of Pathology. 157:2000;1239-1246.
8. Kisilevsky R., Fraser P. Proteoglycans and amyloid fibrillogenesis. Ciba Foundation Symposium. 199:1996;58-67.
9. Kisilevsky R., Szarek W.A. Novel glycosaminoglycan precursors as anti-amyloid agents. Part II. Journal of Molecular Neuroscience. 19:2002;45-50.
10. Lachmann H.J., Booth D.R., Booth S.E., Bybee A., Gilbertson J.A., Gillmore J.D., Pepys M.B., Hawkins P.N. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. The New England Journal of Medicine. 346:2002;1786-1791.
11. Murphy C.L., Eulitz M., Hrncic R., Sletten K., Westermark P., Williams T., Macy S.D., Wooliver C., Wall J., Weiss D.T., Solomon A. Chemical typing of amyloid protein contained in formalin-fixed paraffin-embedded biopsy specimens. American Journal of Clinical Pathology. 116:2001;135-142.
12. O'Nuallain B., Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proceedings of the National Academy of Sciences of the United States of America. 99:2002;1485-1490.
13. Pepys, M. B. (1999). The Lumleian lecture. C-reactive protein and amyloidosis: from proteins to drugs? In G. Williams (Ed.), Horizons in medicine (pp. 397-414). London: Royal College of Physicians of London.
14. Pepys, M. B. (2001). Pathogenesis, diagnosis and treatment of systemic amyloidosis. In C. M. Dobson, R. J. Ellis, & A. R. Fersht (Eds.), Protein misfolding and disease (pp. 203-211). London: The Royal Society.
15. Pepys, M. B., & Hawkins, P. N. (2003). Amyloidosis. In D. A. Warrell, T. M. Cox, J. D. Firth, & E. J. Benz Jr. (Eds.), Oxford textbook of medicine (pp. 162-173). Oxford: Oxford University Press.
16. Pepys M.B., Herbert J., Hutchinson W.L., Tennent G.A., Lachmann H.J., Gallimore J.R., Lovat L.B., Bartfai T., Alanine A., Hertel C., Hoffmann T., Jakob-Roetne R., Norcross R.D., Kemp J.A., Yamamura K., Suzuki M., Taylor G.W., Murray S., Thompson D., Purvis A., Kolstoe S., Wood S.P., Hawkins P.N. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417:2002;254-259.
17. Sacchettini J.C., Kelly J.W. Therapeutic strategies for human amyloid diseases. Nature Review Drug Discovery. 1:2002;267-275.
18. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nature Review Neuroscience. 3:2002;824-828.
19. Sigurdsson E.M., Permanne B., Soto C., Wisniewski T., Frangione B. In vivo reversal of amyloid-beta lesions in rat brain. Journal of Neuropathology and Experimental Neurology. 59:2000;11-17.